Terapia trójskładnikowa w leczeniu nadciśnienia tętniczego – punkt widzenia kardiologa Artykuł przeglądowy

##plugins.themes.bootstrap3.article.main##

Marek Postuła

Abstrakt

W badaniach klinicznych wykazano, że u połowy chorych na nadciśnienie tętnicze jest ono nieprawidłowo kontrolowane, co wiąże się z nieprzestrzeganiem zaleceń lekarskich. Wielu pacjentów wymaga stosowania terapii trójlekowej, żeby osiągnąć zakładane cele leczenia, a obowiązujące wytyczne zalecają połączenia leków o komplementarnych mechanizmach działania. Dostępne jest połączenie trójlekowe o stałym składzie zawierające preparat hamujący układ renina–angiotensyna–aldosteron, antagonistę wapnia i diuretyk tiazydopodobny. Stałe połączenie trójlekowe odznacza się skutecznością, dobrą tolerancją, wygodą stosowania i pozwala osiągnąć prawidłową kontrolę ciśnienia tętniczego.

##plugins.themes.bootstrap3.article.details##

Jak cytować
Postuła , M. (2017). Terapia trójskładnikowa w leczeniu nadciśnienia tętniczego – punkt widzenia kardiologa . Kardiologia W Praktyce, 10(4), 3-9. Pobrano z https://www.journalsmededu.pl/index.php/kwp/article/view/1265
Dział
Artykuły

Bibliografia

1. Zanchetti A., Thomopoulos C., Parati G.: Randomized controlled trials of blood pressure lowering in hypertension: a critical reappraisal. Circ. Res. 2015; 116: 1058-1073.
2. Ettehad D., Emdin C.A., Kiran A. et al.: Blood pressure lowering for prevention of cardiovascular disease and death: a systematic review and meta-analysis. Lancet 2016; 387: 957-967.
3. Kjeldsen S.E., Lund-Johansen P., Nilsson P.M., Mancia G.: Unattended blood pressure measurements in the systolic blood pressure intervention trial: implications for entry and achieved blood pressure values compared with other trials. Hypertension 2016; 67: 808-812.
4. Wright J.T. Jr., Williamson J.D., Whelton P.K. et al.: A randomized trial of intensive versus standard blood-pressure control. N. Engl. J. Med. 2015; 373: 2103-2116.
5. Neutel J.M.: Prescribing patterns in hypertension: the emerging role of fixed-dose combinations for attaining BP goals in hypertensive patients. Curr. Med. Res. Opin. 2008; 24(8): 2389-2401.
6. Xie X., Atkins E., Lv J. et al.: Effects of intensive blood pressure lowering on cardiovascular and renal outcomes: updated systematic review and meta-analysis. Lancet 2016; 387(10017): 435-443.
7. Wald D.S., Law M., Morris J.K. et al.: Combination therapy versus monotherapy in reducing blood pressure: meta-analysis on 11,000 participants from 42 trials. Am. J. Med. 2009; 122(3): 290-300.
8. Berlowitz D.R., Ash A.S., Hickey E.C. et al.: Hypertension management in patients with diabetes: the need for more aggressive therapy. Diabetes Care 2003; 26: 355-359.
9. Psaty B.M., Manolio T.A., Smith N.L. et al.: Time trends in high blood pressure control and the use of antihypertensive medications in older adults: the Cardiovascular Health Study. Arch. Intern. Med. 2002; 162: 2325-2332.
10. Berlowitz D.R., Ash A.S., Hickey E.C. et al.: Inadequate management of blood pressure in a hypertensive population. N. Engl. J. Med. 1998; 339: 1957-1963.
11. Veterans Administration Cooperative Study Group on Antihypertensive Agents (VACSG): Effects of treatment on morbidity in hypertension. Results in patients with diastolic blood pressures averaging 115 through 129 mm Hg. JAMA 1967; 202: 1028-1034.
12. Toth K.: Antihypertensive efficacy of triple combination perindopril/ indapamide plus amlodipine in high-risk hypertensives: results of the PIANIST study (Perindopril-Indapamide plus AmlodipiNe in high rISk hyperTensive patients). Am. J. Cardiovasc. Drugs 2014; 14(2): 137-145.
13. Páll D., Szántó I., Szabó Z.: Triple combination therapy in hypertension: the antihypertensive efficacy of treatment with perindopril, amlodipine, and indapamide SR. Clin. Drug Investig. 2014; 34: 701-708.
14. Chalmers J., Arima H., Woodward M. et al.: Effects of combination of perindopril, indapamide, and calcium channel blockers in patients with type 2 diabetes mellitus: results from the action in diabetes and vascular disease: preterax and diamicron controlled evaluation (ADVANCE) trial. Hypertension 2014; 63(2): 259-264.
15. Fox K.M.; EURopean trial On reduction of cardiac events with Perindopril in stable coronary Artery disease Investigators: Efficacy of perindopril in reduction of cardiovascular events among patients with stable coronary artery disease: randomised, double-blind, placebo-controlled, multicentre trial (the EUROPA study). Lancet 2003; 362: 782-788.
16. Patel A., MacMahon S., Chalmers J. et al.: Effects of a fixed combination of perindopril and indapamide on macrovascular and microvascular outcomes in patients with type 2 diabetes mellitus (the ADVANCE trial): a randomised controlled trial. Lancet 2007; 370: 829-840.
17. Zoungas S., Chalmers J., Neal B. et al.; ADVANCE-ON Collaborative Group: Follow-up of blood-pressure lowering and glucose control in type 2 diabetes. N. Engl. J. Med. 2014; 371: 1392-1406.
18. Beckett N.S., Peters R., Fletcher A.E. et al.; HYVET Study Group: Treatment of hypertension in patients 80 years of age or older. N. Engl. J. Med. 2008; 358: 1887-1898.
19. Dahlöf B., Sever P.S., Poulter N.R. et al.; ASCOT Investigators: Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA): a multicenter randomised controlled trial. Lancet 2005; 366: 895-906.
20. Jamerson K., Weber M.A., Bakris G.L. et al.; ACCOMPLISH Trial Investigators: Benazepril plus amlodipine or hydrochlorothiazide for hypertension in high-risk patients. N. Engl. J. Med. 2008; 359: 2417-2428.
21. Mancia G., Fagard R., Narkiewicz K. et al.: 2013 ESH/ESC guidelines for the management of arterial hypertension: the Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). Eur. Heart J. 2013; 34: 2159-2219.
22. Bramley T.J., Gerbino P.P., Nightengale B.S. et al.: Relationship of blood pressure control to adherence with antihypertensive monotherapy in 13 managed care organizations. J. Manag. Care Pharm. 2006; 12: 239-245.
23. Fung V., Huang J., Brand R. et al.: Hypertension treatment in a medicare population: adherence and systolic blood pressure control. Clin. Ther. 2007; 29: 972-984.
24. Bailey J.E., Wan J.Y., Tang J. et al.: Antihypertensive medication adherence, ambulatory visits, and risk of stroke and death. J. Gen. Intern. Med. 2010; 25: 495-503.
25. Pittman D.G., Tao Z., Chen W. et al.: Antihypertensive medication adherence and subsequent healthcare utilization and costs. Am. J. Manag. Care 2010; 16: 568-576.
26. Dragomir A., Cote R., Roy L. et al.: Impact of adherence to antihypertensive agents on clinical outcomes and hospitalization costs. Med. Care 2010; 48: 418-425.
27. van Wijk B.L., Klungel O.H., Heerdink E.R. et al.: Rate and determinants of 10-year persistence with antihypertensive drugs. J. Hypertens. 2005; 23: 2101-2107.
28. Perreault S., Lamarre D., Blais L. et al.: Persistence with treatment in newly treated middle-aged patients with essential hypertension. Ann. Pharmacother. 2005; 39: 1401-1408.
29. Panjabi S., Lacey M., Bancro T. et al.: Treatment adherence, clinical outcomes, and economics of triple-drug therapy in hypertensive patients. J. Am. Soc. Hypertens. 2013; 7: 46-60.
30. Yang W., Chang J., Kahler K.H. et al.: Evaluation of compliance and health care utilization in patients treated with single pill vs. free combination antihypertensives. Curr. Med. Res. Opin. 2010; 26: 2065-2076.
31. Gupta A.K., Arshad S., Poulter N.R.: Compliance, safety, and effectiveness of fixed-dose combinations of antihypertensive agents: a meta-analysis. Hypertension 2010; 55: 399-407.
32. Cushman W.C., Ford C.E., Cutler J.A. et al.: Success and predictors of blood pressure control in diverse North American settings: the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). J. Clin. Hypertens. 2002; 4: 393-404.
33. UK Prospective Diabetes Study Group: Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. Br. Med. J. 1998; 317: 703-713.
34. Estacio R.O., Jeffers B.W., Gifford N. et al.: Effect of blood pressure control on diabetic microvascular complications in patients with hypertension and type 2 diabetes. Diabetes Care 2000; 23: B54-64.
35. Hebert L.A., Kusek J.W., Greene T. et al.: Effects of blood pressure control on progressive renal disease in blacks and whites [Modification of Diet in Renal Disease Study Group]. Hypertension 1997; 30: 428-435.
36. Hansson L., Zanchetti A., Carruthers S.G. et al.: Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial. HOT Study Group. Lancet 1998; 351: 1755-1762.
37. Wright J.T.J., Agodoa L., Contreras G. et al.: Successful blood pressure control in the African American Study of Kidney Disease and Hypertension. Arch. Intern. Med. 2002; 162: 1636-1643.
38. Jamerson K., Weber M.A., Bakris G.L. et al.; the ACCOMPLISH Trial Investigators: Benazepril plus amlodipine or hydrochlorothiazide for hypertension in high-risk patients. N. Engl. J. Med. 2008; 359: 2417-2428.
39. Marazzi G., Pelliccia F., Campolongo G. et al.: Greater cardiovascular risk reduction with once-daily fixed combination of three antihypertensive agents and statin versus free-drug combination: The ALL-IN-ONE trial. Int. J. Cardiol. 2016; 222: 885-887.